Research Topics
| Christine KatlamaSummaryCountry: France Publications
| Collaborators
|
Detail Information
Publications
Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretroviralsValrie Martinez
Service de Mdecine Interne et Immunologie Clinique, Assistance publique Hpitaux de Paris, INSERM UMR_S 996, Universit Paris Sud, Hpital Antoine Bclre, 157 rue de la Porte de Trivaux, 92141 Clamart, France
BMC Res Notes 5:180. 2012..In HIV and hepatitis C virus (HCV) coinfected patients, the role of antiretroviral therapy (ART) on hepatic steatosis (HS) remains controversial...
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trialsChristine Katlama
Universite Pierre et Marie Curie, Paris VI and Hôpital Pitié Salpêtrière, Paris, France
AIDS 23:2289-300. 2009....- Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trialsChristine Katlama
Universite Pierre et Marie Curie, Paris 6, France
Antivir Ther 15:1045-52. 2010..The 96-week efficacy and safety of the non-nucleoside reverse transcriptase inhibitor (NNRTI) etravirine were evaluated in the Phase III DUET trials... - Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136Christine Katlama
INSERM UMR S 943 and University Pierre and Marie Curie UPMC Paris VI, Paris, France
AIDS 24:2365-74. 2010..Darunavir/ritonavir (darunavir/r) maintenance strategy, in patients with suppressed HIV RNA viremia, is a potential long-term strategy to avoid nucleoside analogue toxicities and to reduce costs... - Dolutegravir for the treatment of HIVChristine Katlama
Pierre et Marie Curie University Paris VI, Hospital Pitié Salpêtrière, Department of Infectious Diseases, Paris, France
Expert Opin Investig Drugs 21:523-30. 2012..EXPERT OPINION: DTG, as other drugs in the INI class, appears safe and well tolerated. Results from ongoing large Phase III studies will bring more generalizable and robust information on the long-term effects of DTG... 
No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patientsJade Ghosn
Department of Infectious and Tropical Diseases, , Paris, France
AIDS 19:1643-7. 2005....- Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patientsDiane Descamps
AP HP, Groupe Hospitalier Bichat Claude Bernard and Université Denis Diderot Paris 7, Laboratoire de Virologie, Paris, France
J Antimicrob Chemother 63:585-92. 2009..The aim of the study was to identify a pattern of protease gene mutations associated with the virological response to darunavir/ritonavir-based regimens... - Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS studyStephanie Dominguez
Département des Maladies Infectieuses et Tropicales INSERM U720, CHU Pitie Salpetriere, Paris, France
J Med Virol 79:105-10. 2007..This add-on pilot study supports the concept of double dose tenofovir to virologically overcome the decreased sensitivity of NRTI-resistant viruses. However, the safety of this regimen needs to be considered carefully... - Structural effects of amino acid variations between B and CRF02-AG HIV-1 integrasesIsabelle Malet
UPMC Universite Paris 06, Paris, France
J Med Virol 80:754-61. 2008..In conclusion, virological response to anti-integrase should be studied carefully, according to the subtype, in clinical trials... - Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patientsIsabelle Malet
Laboratoire de Virologie bâtiment CERVI, Hopital Pitie Salpetriere, EA 2387, Universite Pierre et Marie Curie Paris 6, Paris, France
J Infect 54:367-74. 2007..Moreover, we have evaluated associations between the Gag region sequence and the virological response to Protease Inhibitors (PI)... - Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patientsAnne Genevieve Marcelin
Department of Virology, Pitie Salpftriere Hospital, AP HP, Universite Pierre et Marie Curie, Paris, France
Antivir Ther 12:247-52. 2007..To identify a genotypic score for resistance to saquinavir boosted with ritonavir (SQV/r; 1,000/100 mg twice daily)-based regimens in protease inhibitor (PI)-experienced patients... - Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097)Constance Delaugerre
Department of Virology, Pitié Salpetrière Hospital Paris, Paris, France
J Med Virol 77:345-50. 2005..These results suggest that pharmacological enhancement might overcome viral resistance and that there is some benefit in adding the activity of several boosted-PIs to improve the response to a salvage regimen... - Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological surveyConstance Delaugerre
Department of Virology EA3620, Necker Hospital, Paris, France
AIDS 21:1365-7. 2007..In both cases, infection was caused by CCR5 viruses and no rapid clinical progression to AIDS after primary infection was observed... - Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patientsMarc Wirden
Department of Virology, Pitie Salpetriere Hospital, Paris, France
J Med Virol 76:297-301. 2005..The K65R mutation can emerge even with TAMs or L74V. No obvious impact was shown on the TAMs or other NRTI mutations, although a trend towards emergence of some particular mutations was observed... - Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failureAnne Genevieve Marcelin
Department of Virology, Pitié Salpêtrière Hospital and University Paris VI Pierre et Marie Curie, Paris, France
J Med Virol 72:162-5. 2004.... - Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapyMarc Wirden
Department of Virology, INSERM EMI 0214, Pitie Salpetriere Hospital, Paris, France
Antimicrob Agents Chemother 48:644-7. 2004.... - Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIsMarc Wirden
Department of Virology, , Bichat Hospital, Paris, France
J Clin Microbiol 41:2713-5. 2003..These data suggest that these compounds have lost all of their in vivo antiviral activity in such cases... - Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial)Constance Delaugerre
Department of Virology-EA2387, , Paris, France
Antivir Ther 8:233-7. 2003..CONCLUSION: Administration of IL-2 combined with HAART in HIV-1 infected-patients with advanced disease led to an increase of HIV-1 pro-viral DNA per million PBMC without virological failure or emergence of resistance... - Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patientsPatrick Ingiliz
Hepatology Department, Pitie Salpetriere Hospital, Paris, France
Antivir Ther 13:895-900. 2008..Adefovir dipivoxil (ADV) has shown its efficacy for treating 3TC-resistant (3TC-R) HBV in HIV-coinfected patients. ADV combined with pegylated interferon (PEG-IFN) has never been evaluated in this population... - Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individualsClaudine Duvivier
Department of Infectious Diseases, Pitie Salpetriere Hospital, Paris, France
Antivir Ther 8:603-9. 2003..To evaluate the efficacy and tolerability of indinavir/ritonavir (IDV/RTV) 400/100 mg twice daily in combination with two nucleoside reverse transcriptase inhibitors in antiretroviral-naive patients... - MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II studyChristine Katlama
Département des Maladies Infectieuses et Tropicales INSERM E0214, Hopital Pitie Salpetriere, Paris, France
AIDS 18:1299-304. 2004..MIV-310 (alovudine), a nucleoside reverse transcriptase inhibitor, potently inhibits the replication of highly mutated strains of HIV in vitro. We examined the efficacy of MIV-310 in highly pretreated patients... - Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapySidonie Lambert-Niclot
AP HP, Pitie Salpetriere Hospital, INSERM U 943 and Pierre et Marie Curie University, Paris, France
J Antimicrob Chemother 67:1470-4. 2012.... - Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nCathia Soulie
Université Pierre et Marie Curie Paris, UMR S 943, INSERM, U943, Paris, France
AIDS 23:1605-8. 2009..The NNRTI + protease inhibitor strategy should not be recommended as an antiretroviral first-line regimen, particularly in patients with high viral load at baseline... - Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drugMarc Wirden
Department of Virology, AP HP, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, Paris, France
J Antimicrob Chemother 64:1087-90. 2009..We determined whether raltegravir retains residual antiretroviral activity in vivo against viruses harbouring raltegravir mutations, and thus whether the drug can contribute to the subsequent regimen... - Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patientsFabienne Caby
Service des Maladies Infectieuses et Tropicales, Assistance Publique Hopitaux de Paris, Groupe Hospitalier Pitie Salpetriere, Paris, France
Scand J Infect Dis 42:527-32. 2010..If persistent low viraemia is observed over more than 48 weeks without the emergence of resistance, RAL should never be given as functional monotherapy, as it is associated with a maximal risk of VF and the emergence of RAL resistance... - Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 proteaseSidonie Lambert-Niclot
UPMC Univ Paris 06, EA 2387, F 75005, Paris, France
J Antimicrob Chemother 62:905-8. 2008..To search for genetic factors in the protease and gag regions (NC-p1/TFP-p6/p6pol) involved in selection of darunavir resistance mutations... - Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE studyStephanie Dominguez
AP HP, Département de Maladies Infectieuses et Tropicales, INSERM U720, CHU Pitie Salpetriere, Paris, France
J Antimicrob Chemother 65:2445-9. 2010..To compare plasma antiretroviral concentrations in HIV-HCV co-infected and in matched HIV mono-infected patients... - Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypesAlmoustapha Issiaka Maiga
Department of Virology, Pitie Salpetriere Hospital, AP HP, EA 2387, Universite Pierre et Marie Curie, Paris, France
Antivir Ther 14:123-9. 2009..The genetic barrier for IN inhibitor resistance was compared between HIV-1 subtype B and HIV-1 subtype CRF02_AG, which is highly prevalent in West Africa and becoming more frequent in developed countries... - Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistanceAna Canestri
Department des Maladies Infectieuses, , Paris, France
Antivir Ther 11:561-6. 2006..CONCLUSION: In patients with HIV mutations conferring resistance to all antiretroviral drug classes, foscarnet markedly reduced plasma HIV load and improved immunological status... - HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAARTCathia Soulie
Department of Virology EA2387, Pitie Salpetriere Hospital, University Pierre et Marie Curie, Paris, France
AIDS 21:2243-5. 2007..This suggests that CCR5 antagonist activity should not be compromised in patients harbouring R5 viruses before starting HAART... - Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapySidonie Lambert-Niclot
Department of Virology and Infectious Diseases, AP HP, Pitie Salpetriere Hospital, INSERM U 943 and Pierre et Marie Curie University, Paris, France
J Infect Dis 204:1211-6. 2011..Our objective was to determine virological and clinical characteristics associated with virological failure in human immunodeficiency virus (HIV)-infected patients switching to darunavir/ritonavir (DRV/r) monotherapy... - Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeksSidonie Lambert-Niclot
AP HP, Pitie Salpetriere Hospital, INSERM U 943 and Pierre et Marie Curie University Paris, Paris, France
PLoS ONE 7:e41390. 2012..Our objectives were to study the impact of 96 weeks of Darunavir/ritonavir monotherapy versus a triple standard combination on the HIV-1 blood reservoir and factors associated with HIV-1 plasma DNA at baseline in MONOI trial sub-study... - Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patientsAnne Genevieve Marcelin
Department of Virology, Pitie Salpetriere Hospital, Paris, France
J Med Virol 74:16-20. 2004..There was no relation between the resistance pathways selected with either APV or ritonavir plasma minimal concentration, but higher APV plasma minimal concentration were associated with a lower rate of resistance mutations selection... - Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapySidonie Lambert-Niclot
Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, Paris, France
Antimicrob Agents Chemother 54:4910-3. 2010..The median darunavir seminal plasma concentration was close to the blood plasma free fraction, demonstrating a good penetration of darunavir into the male genital tract... - Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naïve and pre-treated HIV infected patientsBenedicte Roquebert
Department of Virology, Pitié Salpêtrière Hospital and UPRES EA 2387, Universite Pierre et Marie Curie, Paris, France
J Med Virol 79:207-11. 2007..Mutations at position K558 were also associated with the number of thymidine analog mutations (TAMs). These results suggest that these mutations could play a role in NRTI resistance... - Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitorsBenedicte Roquebert
Department of Virology, Pitie Salpetriere Hospital, Paris, France
AIDS 20:287-9. 2006..These minor species, not detected by standard genotype, may influence PI susceptibility... - Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patientsYves Benhamou
Service d Hepato Gastroenterologie, Hopital Pitie Salpetriere, Paris, France
Hepatology 43:548-55. 2006..In conclusion, this retrospective analysis demonstrates the efficacy of TDF against wild-type, presumed precore mutants and LAM-resistant HBV when used as a part of anti-retroviral therapy in HIV-coinfected patients... - Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patientsJade Ghosn
Department of Infectious Diseases, Inserm EO214, , Paris, France
AIDS 17:209-14. 2003..Tolerability of RTV/IDV was excellent. CONCLUSION: RTV/IDV (100/400 mg bid) yields significantly higher IDV plasma Cmin and lower IDV Cmax values relative to the standard IDV regimen, thereby improving both tolerability and efficacy... - Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, MaliAnne Derache
Department of Virology, Pitie Salpetriere Hospital, AP HP, EA 2387, Universite Pierre et Marie Curie, Paris, France
Antivir Ther 12:123-9. 2007..To determine the genetic diversity of HIV-1 reverse transcriptase (RT) and protease sequences and the presence of mutations linked to antiretroviral (ARV) resistance in treatment-naive, HIV-1-infected individuals living in Mali... - Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitroIsabelle Malet
Laboratoire de Virologie, Hopital Pitie Salpetriere, Assistance Publique Hopitaux de Paris, EA 2387, Universite Pierre et Marie Curie Paris 6, Paris, France
Antimicrob Agents Chemother 52:1351-8. 2008..These mutations led to strong impairment of enzymes in vitro in the absence of raltegravir: strand transfer activity was affected, and in some cases 3' processing was also impaired... - Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patientsMarc Wirden
Department of Virology, Pitie Salpetriere Hospital, Paris, France
AIDS 23:95-9. 2009..This lack of knowledge has led to contradictory and confusing attitudes to L74I; although this mutation is not listed by the International AIDS Society - USA, it is increasingly included in several resistance algorithms... - Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 studyRoland Landman
Service des Maladies Infectieuses et Tropicales, AP HP, Groupe Hospitalier Bichat Claude Bernard, Paris, France
J Antimicrob Chemother 64:118-25. 2009..We evaluate the efficacy and tolerability of ritonavir-boosted dual protease inhibitor as a nucleoside reverse transcriptase inhibitor-sparing regimen in a prospective open-label randomized pilot trial in antiretroviral-naive patients... - Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patientsAnne Genevieve Marcelin
Department of Virology, Pitie Salpetriere Hospital, Paris, France
Antimicrob Agents Chemother 48:4687-92. 2004.... - HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimenAnne Genevieve Marcelin
Pitie Salpetriere Hospital, Paris, France
AIDS 21:2341-3. 2007..This highlights the importance of the accessibility of HIV-RNA assays for monitoring treated patients in resource-poor countries to detect early virological failure in order to preserve future therapeutic options... - Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patientsCathia Soulie
UMPC Université Paris 06, Paris, France
AIDS 22:2212-4. 2008..The V3 loop region was rather polymorphic, and 7.3% of patients showed viruses with combinations of mutations in V3 loop previously described to be involved in maraviroc resistance, a licensed CCR5 antagonist... - Antiretroviral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancyJade Ghosn
AP HP, Department of Infectious Diseases, Pitie Salpetriere Hospital, 47 Boulevard de l Hopital, 75013 Paris, France
Antimicrob Agents Chemother 52:1542-4. 2008..At delivery, 26 of 28 women on indinavir-ritonavir had HIV RNA levels of <200 copies/ml. No infant was HIV infected. These data are encouraging for the use of this combination for prevention of mother-to-child transmission of HIV... - Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypesAlmoustapha Issiaka Maiga
Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC University Paris 06, INSERM U943, Paris, France
Antimicrob Agents Chemother 54:728-33. 2010..However, the transmission of drug-resistant viruses with Y181C in a non-B genetic background has a potential for impact on ETR susceptibility... - E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposureSlim Fourati
Université Pierre et Marie Curie Paris, Groupe Hospitalier Pitie Salpetriere, Laboratoire de Virologie, Paris, France
AIDS 26:1619-24. 2012..We show here that APOBEC3 proteins play a role in the emergence of these drug resistance mutations... - Risk factors for raltegravir resistance development in clinical practiceIsabelle Malet
Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC Université Pierre et Marie Curie, INSERM U943, Paris, France
J Antimicrob Chemother 67:2494-500. 2012..To investigate the best conditions of raltegravir use to avoid the selection of resistance mutations in the three main genetic pathways: 148, 155 and 143... - E17A mutation in HIV-1 Vpr confers resistance to didanosine in association with thymidine analog mutationsSlim Fourati
Universite Pierre et Marie Curie, Paris, France
Antiviral Res 93:167-74. 2012..This process may play a role in the kinetics of appearance of drug resistance mutations under antiretroviral treatment... - In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovirOlivier Lada
Virology, AP-HP Pitie-Salpetriere Hospital, Paris, France
Antivir Ther 9:353-63. 2004..The excellent activity of TDF on lamivudine-resistant virus independently of the resistance mutation profile offers an interesting treatment alternative to HIV-HBV coinfected patients... - A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patientsPierre Marie Girard
Service des Maladies Infectieuses et Tropicales, Hopital Saint Antoine, Assistance Publique Hopitaux de Paris, Universite Paris VI, Paris, France
J Antimicrob Chemother 64:126-34. 2009..To assess simplified maintenance regimens containing dual antiretroviral drugs in patients with controlled human immunodeficiency virus type 1 infection... - Natural evolution of CD4+ cell count in patients with CD4 >350 or >500 cells/mm3 at the time of diagnosis according to HIV-1 coreceptor tropismCathia Soulie
UMR S 943, Pierre et Marie Curie University, Paris, France
J Med Virol 84:1853-6. 2012.... - Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: a retrospective repeated liver biopsy analysisPatrick Ingiliz
Hepatology Department, Pitie Salpetriere Hospital, Paris, France
J Hepatol 56:49-54. 2012..The course of the disease is determined by the rapidity of liver fibrosis progression (LFP). The influence of interferon on LFP in coinfected patients has yet not been evaluated by comparative liver biopsies... - Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patientsAnne Genevieve Marcelin
Department of Virology, INSERM EMI 0214, Bichat Claude Bernard Hospital, Paris, France
Antimicrob Agents Chemother 47:594-600. 2003.... - Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patientsAurélie Barrail-Tran
AP HP, Hospital Bicetre, Paris, France
AIDS 24:2581-3. 2010..118 and 3837 vs. 2241 ng/ml) and darunavir area under the curve (AUC(12h)) (50 083 vs. 36 277 ng h/ml). All pharmacokinetic parameters appeared to be highly variable regardless to the addition of etravirine... - Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patientsClaudine Duvivier
AP HP, Groupe Hospitalier Pitie Salpetriere, Service de Maladies Infectieuses et Tropicales, Paris, France
AIDS 23:817-24. 2009..To evaluate the change in bone mineral density (BMD) at specific sites in patients initiating antiretroviral therapy in a substudy of the ANRS 121 trial... - Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094)Roland Tubiana
, INSERM E0214, , Paris, France
Vaccine 23:4292-301. 2005..Detection of such LPR response at the time of treatment interruption was significantly associated with the probability of remaining off therapy. These results provide rationale for future randomized trials exploring this strategy... - Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patientsJean Philippe Bastard
UPMC Université de Paris 06, UMR_S938, INSERM, CdR Saint Antoine, Paris, France
Antivir Ther 17:915-9. 2012..Persistent low-level viral replication could be involved in this inflammatory state. We evaluated whether residual viral load (VL) correlated with the level of systemic inflammatory/immune markers in ART-controlled HIV-infected patients... - Cellular CD4 T cell responses to the diphtheria-derived carrier protein of conjugated pneumococcal vaccine and antibody response to pneumococcal vaccination in HIV-infected adultsClaire Rabian
Laboratoire d Immunologie et d Histocompatibilité, St Louis Hospital, Paris, France
Clin Infect Dis 50:1174-83. 2010..CD4 T cell responses specific to the diphtheria-derived carrier protein CRM(197) were evaluated... - Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIV-hepatitis C virus co-infectionNadia Alatrakchi
Laboratoire d'Immunologie Cellulaire et Tissulaire INSERM U543, , Paris, France
AIDS 18:121-3. 2004..This suggests that IFN+R therapy might compromise virus-specific immune defenses in immunosuppressed patients... - Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3Jean Michel Molina
Assistance Publique Hopitaux de Paris, Department of Infectious Diseases, Hopital St Louis, Paris, France
J Acquir Immune Defic Syndr 46:24-31. 2007..To examine the efficacy and safety of the selected darunavir/r dose further, additional patients were analyzed... - Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trialNathalie de Castro
Department of Infectious Diseases, Assistance Publique Hopitaux de Paris, Saint Louis Hospital and University of Paris VII Denis Diderot, Paris, France
Clin Infect Dis 49:1259-67. 2009..We conducted a prospective, randomized, open-label trial to compare the antiviral efficacy and safety of a switch to raltegravir with the efficacy and safety of continuing enfuvirtide... - Incidence and risk factors of thrombocytopenia in patients receiving intermittent antiretroviral therapy: a substudy of the ANRS 106-window trialMarie Anne Bouldouyre
Department of Infectious Diseases, Hopital Saint Louis, Assistance Publique Hôpitaux de Paris and University of Paris Diderot Paris 7, France
J Acquir Immune Defic Syndr 52:531-7. 2009..Incidence and risk factors for thrombocytopenia in patients discontinuing highly active antiretroviral therapy (HAART) have not been fully investigated... - Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patientsIsabelle Malet
Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC Universite Paris 06, INSERM U943, Paris, France
J Antimicrob Chemother 66:1481-3. 2011.... - Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/mlStéphanie Haïm-Boukobza
Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC Univ Paris, Paris, France
AIDS 25:341-4. 2011..To compare the level of HIV-1 residual viremia, defined by a viral load below 50 copies/ml in patients receiving a tenofovir/emtricitabine and nevirapine (NVP) or efavirenz (EFV)-containing regimen... - Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapyAna Canestri
Hopital Pitie Salpetriere, Paris, France
Clin Infect Dis 50:773-8. 2010..We report data on 11 patients with neurological symptoms and human immunodeficiency virus (HIV) cerebrospinal fluid (CSF) viremia contrasting with suppressed plasma HIV RNA during receipt of combined antiretroviral therapy... - Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapyAmelie Guihot
UPMC Univ Paris 06, INSERM, UMR945, AP HP, Laboratoire d Immunologie Cellulaire et Tissulaire, Hopital Pitie Salpetriere, Paris, France
AIDS 24:614-7. 2010..Long-term and efficient antiretroviral therapy provides continuous benefits both on the immune system and on the HIV reservoirs... - Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapyPatrick Ingiliz
Hepatology Department, AP HP, GH Pitié Salpétrière, Paris, France
Hepatology 49:436-42. 2009..Conclusions: HIV-infected patients on combined antiretroviral therapy with chronic transaminase elevation of unknown origin have a high rate of liver lesions, mostly consistent with NASH related to insulin resistance... - Modulation of interleukin-7 receptor expression characterizes differentiation of CD8 T cells specific for HIV, EBV and CMVFrançois Boutboul
Laboratoire d Immunologie Cellulaire, Hopital Pitie Salpetriere, Universite Pierre et Marie Curie, Paris, France
AIDS 19:1981-6. 2005.... - Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patientsVincent Thibault
Virology Laboratory, Hopital Pitie Salpetriere, Assistance Publique, Paris, France
Antivir Ther 16:199-205. 2011..Our main objective was to study the kinetics of HBsAg level in HIV-HBV-coinfected patients with undetectable HBV DNA load under treatment containing tenofovir disoproxil fumarate (TDF)...